Avalo Therapeutics Analyst Ratings
Avalo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | -13.29% | Jefferies | → $3 | Downgrades | Hold → Underperform |
| 03/03/2022 | -78.32% | Jefferies | $5 → $0.75 | Downgrades | Buy → Hold |
| 03/03/2022 | 15.61% | RBC Capital | $5 → $4 | Maintains | Outperform |
| 09/24/2021 | 73.41% | RBC Capital | → $6 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/08/2023 | -13.29% | 傑富瑞 | →$3 | 評級下調 | 持有→表現不佳 |
| 03/03/2022 | -78.32% | 傑富瑞 | $5→$0.75 | 評級下調 | 購買→Hold |
| 03/03/2022 | 15.61% | 加拿大皇家銀行資本 | $5→$4 | 維護 | 跑贏大盤 |
| 09/24/2021 | 73.41% | 加拿大皇家銀行資本 | →$6 | 開始承保 | →跑贏大盤 |
What is the target price for Avalo Therapeutics (AVTX)?
阿瓦洛治療公司(AVTX)的目標價格是多少？
The latest price target for Avalo Therapeutics (NASDAQ: AVTX) was reported by Jefferies on February 8, 2023. The analyst firm set a price target for $3.00 expecting AVTX to fall to within 12 months (a possible -13.29% downside). 3 analyst firms have reported ratings in the last year.
傑富瑞於2023年2月8日報道了阿瓦洛治療公司(納斯達克：AVTX)的最新目標價。這家分析公司將目標價定為3.00美元，預計AVTX將在12個月內下跌(跌幅可能為-13.29%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Avalo Therapeutics (AVTX)?
Avalo治療公司(AVTX)的最新分析師評級是什麼？
The latest analyst rating for Avalo Therapeutics (NASDAQ: AVTX) was provided by Jefferies, and Avalo Therapeutics downgraded their underperform rating.
傑富瑞提供了對阿瓦洛治療公司(納斯達克代碼：AVTX)的最新分析師評級，阿瓦洛治療公司下調了其表現不佳的評級。
When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?
Avalo治療公司(AVTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與阿瓦洛治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Avalo治療公司的上一次評級是在2023年2月8日提交的，所以你應該預計下一次評級將在2024年2月8日左右提供。
Is the Analyst Rating Avalo Therapeutics (AVTX) correct?
分析師對Avalo Treeutics(AVTX)的評級正確嗎？
While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a downgraded with a price target of $0.00 to $3.00. The current price Avalo Therapeutics (AVTX) is trading at is $3.46, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Avalo治療公司(AVTX)評級被下調，目標價為0.00美元至3.00美元。Avalo治療公司(AVTX)目前的交易價格為3.46美元，超出了分析師的預測範圍。